ENZON PHARMACEUTICALS
About Enzon
Technology Platforms
Research & Development
Marketed Products
Partnering
Newsroom
Investors
Careers
Contact Us


ENZON HEADER PIC
Home > Investors
Analyst Coverage Annual Reports Press Releases SEC Filings
Request Information Calendar of Events E-mail Alerts Stock Quote Stock Lookup Corporate Governance Contact Us
Press Releases
Print Print page     Email Email page

All Releases

May 7, 2008
Enzon Reports Strong First Quarter 2008 Results PDF 16.0 KB Add to Briefcase

May 7, 2008
Enzon Pharmaceuticals, Inc. Announces Plan to Spin-off Biotechnology Business PDF 8.3 KB Add to Briefcase

Apr 30, 2008
Enzon to Release First Quarter 2008 Earnings on Wednesday, May 7, 2008 PDF 5.4 KB Add to Briefcase

Apr 23, 2008
Cimzia(R), Utilizing Enzon's Pegylation Technology, Approved in the U.S. PDF 7.4 KB Add to Briefcase

Apr 9, 2008
Enzon to Present Preclinical Data On HIF-1alpha antagonist at AACR PDF 5.0 KB Add to Briefcase

Mar 17, 2008
Enzon's PEG-SN38 Featured in Clinical Cancer Research PDF 8.0 KB Add to Briefcase

Feb 14, 2008
Enzon Reports Significant Progress on the Reduction of Its Debt PDF 5.6 KB Add to Briefcase

Feb 14, 2008
Enzon Reports Solid 2007 Results PDF 25.5 KB Add to Briefcase

Feb 12, 2008
Enzon Pharmaceuticals to Add New Independent Director to Board PDF 5.9 KB Add to Briefcase

Feb 8, 2008
Enzon to Release Earnings on Thursday, February 14, 2008; Conference Call and Webcast to Follow PDF 4.8 KB Add to Briefcase

Dec 10, 2007
Enzon Presents New PEG-SN38 Preclinical Data at ASH PDF 7.3 KB Add to Briefcase

Nov 29, 2007
Enzon to Present at BMO Capital Markets Focus on Healthcare Conference

Oct 30, 2007
Enzon Initiates Second Phase 1 Study of Its HIF-1 Alpha Antagonist

Oct 30, 2007
Enzon Provides New Data on Customized Linker Technology

Oct 30, 2007
Enzon Reports Third Quarter 2007 Results

Oct 26, 2007
Enzon to Webcast Live from Investor Day in NYC

Sep 26, 2007
Enzon Pharmaceuticals to Sponsor Investor Day in NYC

Sep 6, 2007
Enzon to Present at Bear Stearns 20th Annual Healthcare Conference

Aug 20, 2007
Enzon to Eliminate Its Remaining 2008 Convertible Debt

Aug 2, 2007
Enzon Reports Second Quarter 2007 Results

Showing 1-20 of 224 Page: 1 2 3 ... 12  Next 20
= add release to Briefcase
 

 

 

Stock Information
(ENZN) NASD
Last Trade 9.350
Change(%) + 0.03
Volume 136,600
May 9, 2008 12:48 PM ET
New Product Release
Lab Look
Our four proprietary marketed brands are ABELCET®, ADAGEN®, DEPOCYT®, and ONCASPAR®. To learn more about our recent product releases CLICK HERE
Shareholder Tools
  • Briefcase Shareholder Briefcase
  • Printed Materials Printed Materials
  • Email Alerts Email Alerts
  • Download Center Download Library
  • Glossary Glossary
  • RSS RSS News Feeds

  • Search Investor Relations


Copyright © 2005-2007 Enzon Pharmaceuticals, Inc. All rights reserved.
Terms of Use
Privacy Information